<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-title>BMC Neurology</journal-title><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2377-8-48</article-id><article-id pub-id-type="pmid">19091059</article-id><article-id pub-id-type="doi">10.1186/1471-2377-8-48</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Role of <italic>MAPT </italic>mutations and haplotype in frontotemporal lobar degeneration in Northern Finland</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Kaivorinne</surname><given-names>Anna-Lotta</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>annalott@mail.student.oulu.fi</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Kr&#x000fc;ger</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>johanna.kruger@oulu.fi</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Kuivaniemi</surname><given-names>Katja</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>katja.kuivaniemi@mail.suomi.net</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tuominen</surname><given-names>Hannu</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>hannu.tuominen@ppshp.fi</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Moilanen</surname><given-names>Virpi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>virpi.moilanen@ppshp.fi</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Majamaa</surname><given-names>Kari</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>kari.majamaa@utu.fi</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Remes</surname><given-names>Anne M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>anne.remes@oulu.fi</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Neurology, University of Oulu, Oulu, Finland</aff><aff id="I2"><label>2</label>Clinical Research Center, Oulu University Hospital, Oulu, Finland</aff><aff id="I3"><label>3</label>Department of Pathology, University of Oulu, Oulu, Finland</aff><aff id="I4"><label>4</label>Department of Neurology, University of Turku, Turku, Finland</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2008</year></pub-date><volume>8</volume><fpage>48</fpage><lpage>48</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/8/48"/><history><date date-type="received"><day>15</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Kaivorinne et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Kaivorinne et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Kaivorinne Anna-Lotta annalott@mail.student.oulu.fi </dc:author><dc:title> Role of MAPT mutations and haplotype in frontotemporal lobar degeneration in Northern Finland </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Neurology 8(1): 48-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2377(2008)8:1&#x0003c;48&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2377</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Frontotemporal lobar degeneration (FTLD) consists of a clinically and neuropathologically heterogeneous group of syndromes affecting the frontal and temporal lobes of the brain. Mutations in microtubule-associated protein tau (<italic>MAPT</italic>), progranulin (<italic>PGRN</italic>) and charged multi-vesicular body protein 2B (<italic>CHMP2B</italic>) are associated with familial forms of the disease. The prevalence of these mutations varies between populations. The H1 haplotype of <italic>MAPT </italic>has been found to be closely associated with tauopathies and with sporadic FTLD. Our aim was to investigate <italic>MAPT </italic>mutations and haplotype frequencies in a clinical series of patients with FTLD in Northern Finland.</p></sec><sec sec-type="methods"><title>Methods</title><p><italic>MAPT </italic>exons 1, 2 and 9&#x02013;13 were sequenced in 59 patients with FTLD, and <italic>MAPT </italic>haplotypes were analysed in these patients, 122 patients with early onset Alzheimer's disease (eoAD) and 198 healthy controls.</p></sec><sec><title>Results</title><p>No pathogenic mutations were found. The H2 allele frequency was 11.0% (<italic>P </italic>= 0.028) in the FTLD patients, 9.8% (<italic>P </italic>= 0.029) in the eoAD patients and 5.3% in the controls. The H2 allele was especially clustered in patients with a positive family history (<italic>P </italic>= 0.011) but did not lower the age at onset of the disease. The ApoE4 allele frequency was significantly increased in the patients with eoAD and in those with FTLD.</p></sec><sec><title>Conclusion</title><p>We conclude that although pathogenic <italic>MAPT </italic>mutations are rare in Northern Finland, the <italic>MAPT </italic>H2 allele may be associated with increased risks of FTLD and eoAD in the Finnish population.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Frontotemporal lobar degeneration (FTLD) is a clinically and neuropathologically heterogeneous group of neurodegenerative disorders affecting the frontal and/or temporal lobes and causing changes in personal and social conduct, disinhibition and progressive changes in language. The main clinical syndromes are frontotemporal dementia (FTD), semantic dementia (SD) and progressive non-fluent aphasia (PA).[<xref ref-type="bibr" rid="B1">1</xref>] FTLD can be divided neuropathologically into diseases with tau-positive inclusions and diseases with tau-negative and ubiquitin-positive inclusions.[<xref ref-type="bibr" rid="B2">2</xref>] A positive family history is present in 30&#x02013;50% of FTLD cases.[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>] Mutations in microtubule-associated protein tau (<italic>MAPT</italic>), progranulin <italic>(PGRN) </italic>and charged multi-vesicular body protein 2B (<italic>CHMP2B</italic>) are associated with the autosomal dominant form of the disease. [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B9">9</xref>]</p><p>Mutations in <italic>MAPT </italic>are associated with tau-positive neuropathology and occur in familial FTLD in frequencies that vary in the range 5&#x02013;50% between populations.[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B15">15</xref>] Several polymorphisms throughout the <italic>MAPT </italic>gene are in complete linkage disequilibrium with each other and are inherited as two separate haplotypes, H1 and H2. The predominant haplotype, H1, has been found to be associated with sporadic tauopathies, [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>] and also to have a faint association with FTLD.[<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>] However, in some studies the H2 haplotype has also been found to be associated with FTLD.[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B21">21</xref>]</p><p>The aim of this work was to investigate the frequency of <italic>MAPT </italic>mutations in Finnish patients with FTLD and to examine the association between the <italic>MAPT </italic>haplotypes and FTLD. We sequenced exons 1, 2 and 9&#x02013;13 of <italic>MAPT </italic>in 59 Finnish patients with FTLD and analysed the <italic>MAPT </italic>haplotypes in these patients, 122 patients with early onset Alzheimer's disease (eoAD, age at onset before 65 years) and 198 healthy middle-aged controls.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>We examined 59 patients with FTLD (mean age at onset 58.5 years, range 38&#x02013;79, 49% men) and 122 patients with eoAD (mean age 58.2 years, range 38&#x02013;64, 45% men) in the memory clinic of the Department of Neurology, Oulu University Hospital, Finland, during the years 1999&#x02013;2006. Population of the Northern Ostrobothnia area served by this hospital was 380 668 (as of 31.12.2006). A clinical diagnosis of FTLD was made according to the criteria of Lund and Manchester, and the NINCDS-ADRDA criteria were used to establish a diagnosis of probable AD.[<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>] The FTLD group consisted of 34 (58%) patients with FTD, 19 (32%) with PA and six (10%) with SD. Six patients (10%) also suffered from symptoms of motor neuron disease. 27% of the patients in the FTLD group had a positive family history of FTLD, i.e. a first-degree relative suffering from dementia. PGRN gene mutations in the FTLD patients were excluded by direct sequencing as described previously.[<xref ref-type="bibr" rid="B24">24</xref>] Most of the patients were alive during this study and neuropathological examinations were performed only on five deceased subjects.</p><p>Control samples were obtained from 198 healthy anonymous middle-aged volunteers (mean age 40.6 years, range 19&#x02013;64 years) as part of blood donations at Finnish Red Cross offices in the capitals of the provinces of Northern and Central Ostrobothnia and Kainuu.</p><p>Written informed consent was obtained from all the patients or their guardians. The research protocols were approved by the Ethics Committees of the Faculty of Medicine at the University of Oulu, the Northern Ostrobothnia Hospital District and the Finnish Red Cross.</p></sec><sec sec-type="methods"><title>Methods</title><p>Total genomic DNA was extracted from the blood samples by the standard sodium dodecyl sulphate-proteinase K method. <italic>MAPT </italic>exons 1, 2 and 9&#x02013;13 were amplified by polymerase chain reaction using genomic primers designed to cover the flanking intronic sequences as well. These exons were selected, because pathogenic mutations in <italic>MAPT </italic>have been associated to exons 1 and 9&#x02013;13. Exon 2 was randomly selected to add data of polymorphisms between H1 and H2 haplotypes. Sequencing was carried out using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) and the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).</p><p>The <italic>MAPT </italic>haplotype was determined by testing for the presence of a 238 bp deletion between exons 9 and 10, which is characteristic of the H2 haplotype.[<xref ref-type="bibr" rid="B25">25</xref>] The haplotypes were assessed by visualizing the PCR products on a 1.5% agarose gel.</p><p>A novel exon13 +67delAAT polymorphism was screened by PCR using mismatch primers (forward 5'-GAGATCGTGTACAAGTCGCCAGT-3' and reverse 5'-AGAGGGCGGGGGCCGGGTCAAT-3'). The amplified fragments were digested with <italic>SspI </italic>restriction enzyme and then visualized using a 5% Metaphor gel. The apolipoprotein E (ApoE) genotype was determined as described previously.[<xref ref-type="bibr" rid="B26">26</xref>]</p><p>Statistical analyses were performed using the SPSS 16.0 software for Windows. The minimum significance level was set at <italic>P </italic>= 0.05. Differences in allele distributions were analysed using the &#x003c7;<sup>2 </sup>test. Fisher's exact test was used to analyse contingency tables when the expected value was less than five. Binary logistic regression analyses were performed to estimate both the marginal and partial (i.e. correcting for age, gender and ApoE4 allele) potential effects of genetic patterns.</p></sec></sec><sec><title>Results</title><p>We sequenced exons 1, 2 and 9&#x02013;13 of the <italic>MAPT </italic>gene in 59 Finnish patients with FTLD and analysed <italic>MAPT </italic>haplotypes in these patients, 122 patients with eoAD and 198 middle-aged healthy controls. No pathogenic <italic>MAPT </italic>mutations were found in the patients with FTLD.</p><p>We detected seven polymorphic sites which have previously been found to be associated with the H2 haplotype (Table <xref ref-type="table" rid="T1">1</xref>), but did not find any novel polymorphisms in the H2 haplotype. The previously described Thr39Thr, P270P, Exon10 -47 and Exon11 +90, Exon11 +104 polymorphisms were found to be associated with the H1 allele (Table <xref ref-type="table" rid="T2">2</xref>), in addition to a novel polymorphism Exon13 +67delAAT, which was found in 10 H1 alleles of patients with FTLD. One H1/H1 homozygous patient was also homozygous for the Exon13 +67delAAT polymorphism. The frequencies of Exon13 +67delAAT were 9.5% among the FTLD patients with the H1 allele, 8.5% in the whole FTLD group, 5.9% in the AD patients and 3.2% in healthy controls. Results of a neuropathological examination were available for one man with this polymorphism, who had had FTLD with ALS (amyotrophic lateralis sclerosis), for six years with onset at the age of 59 years. These results revealed tau-negative, ubiquitin-positive FTLD and motor neuron disease.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Polymorphisms in the H2 haplotype</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Exon</bold></td><td align="left"><bold>Position Relative to Exon</bold></td><td align="left"><bold>Codon</bold></td><td align="left"><bold>Nucleotide Change</bold></td></tr></thead><tbody><tr><td align="left">5' UTR</td><td align="left">-13 from ATG</td><td></td><td align="left">A &#x0003e; G</td></tr><tr><td align="left">Exon 2</td><td align="left">-93</td><td></td><td align="left">T &#x0003e; C</td></tr><tr><td></td><td align="left">+18</td><td></td><td align="left">C &#x0003e; T</td></tr><tr><td align="left">Exon 9</td><td></td><td align="left">A227A</td><td align="left">GCA &#x0003e; GCG</td></tr><tr><td></td><td></td><td align="left">N255N</td><td align="left">AAT &#x0003e; AAC</td></tr><tr><td align="left">Exon 11</td><td align="left">+34</td><td></td><td align="left">G &#x0003e; A</td></tr><tr><td align="left">Exon 13</td><td align="left">+34</td><td></td><td align="left">T &#x0003e; C</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Polymorphisms in the H1 haplotype</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Exon</bold></td><td align="left"><bold>Position Relative to Exon</bold></td><td align="left"><bold>Codon</bold></td><td align="left"><bold>Nucleotide Change</bold></td><td align="left"><bold>Allele Frequency in Patients with FTLD</bold></td></tr></thead><tbody><tr><td align="left">Exon 1</td><td></td><td align="left">T39T</td><td align="left">ACG &#x0003e; ACA</td><td align="left">3</td></tr><tr><td align="left">Exon 2</td><td></td><td align="left">T52A</td><td align="left">ACT &#x0003e; GCT</td><td align="left">1</td></tr><tr><td align="left">Exon 9</td><td></td><td align="left">P270P</td><td align="left">CCG &#x0003e; CCA</td><td align="left">1</td></tr><tr><td align="left">Exon 10</td><td align="left">-47</td><td></td><td align="left">C &#x0003e; A</td><td align="left">2</td></tr><tr><td align="left">Exon 11</td><td align="left">+90</td><td></td><td align="left">G &#x0003e; A</td><td align="left">16</td></tr><tr><td align="left">Exon 11</td><td align="left">+104</td><td></td><td align="left">A &#x0003e; G</td><td align="left">1</td></tr><tr><td align="left">Exon 13</td><td align="left">+67</td><td></td><td align="left">del AAT</td><td align="left">10</td></tr></tbody></table></table-wrap><p>The frequencies of the H2 allele were 11.0% in the patients with FTLD and 9.8% in those with eoAD, as opposed to 5.3% in the controls (Table <xref ref-type="table" rid="T3">3</xref>). Thus the frequencies of the H2 allele and the genotypes H1/H2 + H2/H2 were significantly increased in the FTLD patients relative to the controls (Table <xref ref-type="table" rid="T3">3</xref> and Table <xref ref-type="table" rid="T4">4</xref>), and they also showed a significant increase among the patients with eoAD. The H2 allele was clustered with the familial form of FTLD, so that a positive family history was found in 58% of the FTLD cases with the H1/H2 or H2/H2 genotype (Fisher's exact test, <italic>P </italic>= 0.011). The H2 allele was not associated with onset of the disease at an earlier age, the age at onset being 56.0 &#x000b1; 6.7 years (mean &#x000b1; SD) in the H1/H2 or H2/H2 carriers, and 59.2 &#x000b1; 6.5 years in the H1/H1 carriers (<italic>P </italic>= 0.138).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>MAPT genotypes and haplotypes in patients with FTLD and eoAD</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Sample</bold></td><td align="center" colspan="5"><bold>Genotypes</bold></td><td align="center" colspan="4"><bold>Haplotypes</bold></td></tr><tr><td></td><td colspan="5"><hr></hr></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center"><bold>N</bold><break/><bold>Individuals</bold></td><td align="center"><bold>H1/H1</bold><break/><bold>N (%)</bold></td><td align="center"><bold>H1/H2</bold><break/><bold>N (%)</bold></td><td align="center"><bold>H2/H2</bold><break/><bold>N (%)</bold></td><td align="center"><bold>Genotype vs. controls<sup>b</sup></bold></td><td align="center"><bold>N</bold><break/><bold>Alleles</bold></td><td align="center"><bold>H1</bold><break/><bold>N (%)</bold></td><td align="center"><bold>H2</bold><break/><bold>N (%)</bold></td><td align="center"><bold>Haplotypes vs. controls</bold></td></tr></thead><tbody><tr><td align="left"><bold>FTLD</bold></td><td align="center">59</td><td align="center">47 (79.7)</td><td align="center">11 (18.6)</td><td align="center">1 (1.7)</td><td align="center"><italic>P </italic>= 0.018<sup>a</sup></td><td align="center">118</td><td align="center">105 (89.0)</td><td align="center">13 (11.0)</td><td align="center"><italic>P </italic>= 0.028<sup>a</sup></td></tr><tr><td align="left"><bold>EoAD</bold></td><td align="center">122</td><td align="center">98 (80.3)</td><td align="center">24 (19.7)</td><td align="center">0</td><td align="center"><italic>P </italic>= 0.006<sup>a</sup></td><td align="center">244</td><td align="center">220 (90.2)</td><td align="center">24 (9.8)</td><td align="center"><italic>P </italic>= 0.029<sup>a</sup></td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">198</td><td align="center">180 (90.9)</td><td align="center">15 (7.6)</td><td align="center">3 (1.5)</td><td></td><td align="center">396</td><td align="center">375 (94.7)</td><td align="center">21 (5.3)</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>Indicates statistical significance</p><p><sup>b </sup>The genotypes were grouped into H1/H1 and H1/H2 + H2/H2 for statistical analysis</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Logistic regression analysis on different variables in FTLD and eoAD</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>FTLD</bold></td><td></td><td align="left"><bold>eoAD</bold></td><td></td></tr><tr><td></td><td align="left"><bold><sup>d</sup>OR (95% CI)</bold></td><td align="left"><bold><italic>P</italic></bold></td><td align="left"><bold>OR (95% CI)</bold></td><td align="left"><bold><italic>P</italic></bold></td></tr></thead><tbody><tr><td align="left"><bold>MAPT genotype<sup>a</sup></bold></td><td align="left">2.93 (1.00&#x02013;8.55)</td><td align="left">0.050</td><td align="left">2.04 (0.77&#x02013;5.41)</td><td align="left">0.155</td></tr><tr><td align="left"><bold>ApoE4+<sup>b</sup></bold></td><td align="left">1.21 (0.53&#x02013;2.76)</td><td align="left">0.649</td><td align="left">2.97 (1.49&#x02013;5.93)</td><td align="left">0.002</td></tr><tr><td align="left"><bold>Gender<sup>c</sup></bold></td><td align="left">1.88 (0.85&#x02013;4.19)</td><td align="left">0.121</td><td align="left">1.92 (0.97&#x02013;3.77)</td><td align="left">0.060</td></tr><tr><td align="left"><bold>Age</bold></td><td align="left">1.24 (1.16&#x02013;1.32)</td><td align="left">&#x0003c; 0.001</td><td align="left">1.22 (1.16&#x02013;1.27)</td><td align="left">&#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p>Reference values: H1-genotype<sup>a</sup>, absence of ApoE4 allele<sup>b</sup>, male<sup>c</sup>, <sup>d</sup>95% CI = 95% confidence interval.</p></table-wrap-foot></table-wrap><p>Only one patient, with a negative family history of neurological disorders, had the H2/H2 genotype. In this case progressive aphatic symptoms and changes in personality had started at the age of 52 years and by the end-stage of the disease he was completely aphatic and had evident extrapyramidal symptoms. He died at the age of 62 years. Neuropathological evaluation revealed marked atrophy in both the frontal and temporal lobes. Tau-pathology was widespread. Tangle-like, globose and granular neuronal inclusions were present in neocortex, other than occipitally, and in the hippocampal pyramidal and fascia dentata neurones, basal ganglia, substantia nigra, locus ceruleus and cerebellar dentate. Tau-positive neuropil threads were seen in the same areas and in the subcortical white matter, and some white matter glial cells were tau-positive. Beta-amyloid and synuclein were absent.</p><p>The ApoE4 allele was found in 42.4% of the FTLD patients and 63.1% of the eoAD patients, the latter frequency being significantly increased (<italic>P </italic>&#x0003c; 0.001), but the former less so (<italic>P </italic>= 0.049).</p></sec><sec><title>Discussion</title><p>We analysed <italic>MAPT </italic>mutations and the role of the <italic>MAPT </italic>haplotype in 59 patients with FTLD in Northern Finland. A positive family history was found in 27% of these patients, but no pathogenic mutations in <italic>MAPT </italic>were detected. The relative frequency of <italic>MAPT </italic>mutations has varied previously between 0 and 50% depending on type of study, the area concerned and whether there has been a family history of the disease, [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>] although the differences in frequency may also be explained by varying methods of case ascertainment. The frequency is obviously higher in familial forms of FTLD, however, an effect that has been attributed to the founder mutation in France and the Netherlands.[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B12">12</xref>] Interestingly, very low frequencies of <italic>MAPT </italic>mutations have been reported in Sweden and Poland.[<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>] The roots of the Finnish population reach back over 2000 years, but internal migration to Northern Ostrobothnia in the 16th century created a regional subisolate in the population of some 380000 inhabitants examined here,[<xref ref-type="bibr" rid="B29">29</xref>] which may explain the extremely low <italic>MAPT </italic>mutation frequency. On the other hand, the geographical variation may reflect differences in the prevalence of <italic>MAPT </italic>mutations between populations. Our data support the findings of very low frequencies of <italic>MAPT </italic>mutations in the Baltic countries.[<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]</p><p>We found that the H2 allele frequencies in patients with either FTLD or eoAD were two-fold compared with those in the controls, and that the frequencies of both the H2 allele and the H1/H2 + H2/H2 genotypes were significantly higher in both patient groups. The H2 allele in particular was associated with the familial form of FTLD. The H1 haplotype is the most common, having an allele frequency of about &#x0003e; 70% in European populations,[<xref ref-type="bibr" rid="B30">30</xref>] while the H2 haplotype has been associated with Caucasian ancestry, since Middle Eastern and European populations have frequencies of about 25%, the Finnish population about 8% and Central Asian populations about 5%, while the allele is essentially practically non-existent in other populations.[<xref ref-type="bibr" rid="B30">30</xref>] H1 has been associated with sporadic tauopathies, including Parkinson's disease,[<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>] progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD),[<xref ref-type="bibr" rid="B18">18</xref>] and it also has a putative association with FTD.[<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>] In particular, the H1c variant of the H1 haplotype has been linked with CBD, PSP and AD.[<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B31">31</xref>] Recently, however, the H2 haplotype has been found to increase the risk of familial FTD in an Italian population.[<xref ref-type="bibr" rid="B21">21</xref>] Two Belgian families with FTLD have been linked with the extended rare H2 haplotype and a <italic>PGRN </italic>mutation.[<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B15">15</xref>] However, no pathogenic mutations in <italic>PGRN </italic>were found in our cohort.[<xref ref-type="bibr" rid="B24">24</xref>] The H2 haplotype has also been reported to lower the age of onset of the disease,[<xref ref-type="bibr" rid="B32">32</xref>] but this finding could not be confirmed in the present study. Interestingly, this is the first study showing the association between the H2 haplotype and Alzheimer's disease.</p><p>The H2 haplotype is assumed to be an ancestral one and to manifest only minor variability,[<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B33">33</xref>] as confirmed here. A novel polymorphism Exon 13 +67 delAAT was found to be associated with the H1 allele and to have an increased frequency in patients with FTLD and eoAD, although it was also frequent in the controls, thus suggesting a non-pathogenic nature.</p><p>A significant association was found between the ApoE4 allele, the most important genetic risk factor for AD, and eoAD, and a similar association was also evident with FTLD. Increased frequency of the ApoE4 allele in patients with FTLD has also been reported previously,[<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B34">34</xref>] and it has also been found to increase the penetrance of dementia, since valosin-containing protein (VCP) is associated with FTD,[<xref ref-type="bibr" rid="B35">35</xref>] and to impair long-term memory functions and reduce parahippocampal perfusion in FTLD patients.[<xref ref-type="bibr" rid="B36">36</xref>]</p></sec><sec><title>Conclusion</title><p>We conclude that, although pathogenic <italic>MAPT </italic>mutations are rare in Northern Finland, the frequency of the H2 allele of <italic>MAPT </italic>is significantly increased in patients with FTLD and also in patients with eoAD. Either the H2 haplotype itself or other genetic variations associated with it may be a risk factor for FTLD and eoAD in the Finnish population.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>A-LK participated in the design of the research, carried out the molecular genetic studies, performed the statistical analysis and drafted the manuscript. JK participated in the examination of the patients, carried out some of the molecular genetic studies and helped to draft the manuscript. KK participated in the analysis of the patient data. HT carried out the neuropathological examinations. VM participated in the examination of the patients. KM participated in the design of the research and helped to draft the manuscript. AMR developed the idea of the research initially, participated in its design and coordination and helped to draft the manuscript. All the authors have read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/8/48/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants from the Finnish Medical Foundation and the P&#x000e4;ivikki and Sakari Sohlberg Foundation (AMR). We thank Ms Anja Heikkinen and Ms Pirjo Ker&#x000e4;nen for their excellent technical assistance.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Snowden</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name></person-group><article-title>Frontotemporal dementia</article-title><source>Lancet Neurol</source><year>2005</year><volume>4</volume><fpage>771</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">16239184</pub-id><pub-id pub-id-type="doi">10.1016/S1474-4422(05)70223-4</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Hatanpaa</surname><given-names>KJ</given-names></name><name><surname>White</surname><given-names>CL</given-names><suffix>3rd</suffix></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Lowe</surname><given-names>JS</given-names></name><name><surname>Holm</surname><given-names>IE</given-names></name><name><surname>Tolnay</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Yokoo</surname><given-names>H</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name><name><surname>Woulfe</surname><given-names>J</given-names></name><name><surname>Munoz</surname><given-names>DG</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name></person-group><article-title>Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration</article-title><source>Acta Neuropathol</source><year>2007</year><volume>114</volume><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17579875</pub-id><pub-id pub-id-type="doi">10.1007/s00401-007-0237-2</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poorkaj</surname><given-names>P</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Steinbart</surname><given-names>E</given-names></name><name><surname>Payami</surname><given-names>H</given-names></name><name><surname>Sadovnick</surname><given-names>A</given-names></name><name><surname>Nochlin</surname><given-names>D</given-names></name><name><surname>Tabira</surname><given-names>T</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Borson</surname><given-names>S</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Reich</surname><given-names>S</given-names></name><name><surname>Quinn</surname><given-names>B</given-names></name><name><surname>Schellenberg</surname><given-names>G</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name></person-group><article-title>Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia</article-title><source>Arch Neurol</source><year>2002</year><volume>58</volume><fpage>383</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">11255441</pub-id><pub-id pub-id-type="doi">10.1001/archneur.58.3.383</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosso</surname><given-names>SM</given-names></name><name><surname>Donker Kaat</surname><given-names>L</given-names></name><name><surname>Baks</surname><given-names>T</given-names></name><name><surname>Joosse</surname><given-names>M</given-names></name><name><surname>de Koning</surname><given-names>I</given-names></name><name><surname>Pijnenburg</surname><given-names>Y</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Dooijes</surname><given-names>D</given-names></name><name><surname>Kamphorst</surname><given-names>W</given-names></name><name><surname>Ravid</surname><given-names>R</given-names></name><name><surname>Niermeijer</surname><given-names>MF</given-names></name><name><surname>Verheij</surname><given-names>F</given-names></name><name><surname>Kremer</surname><given-names>HP</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name></person-group><article-title>Frontotemporal dementia in the Netherlands: patient characteristics and prevalence estimates from a population-based study</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>2016</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">12876142</pub-id><pub-id pub-id-type="doi">10.1093/brain/awg204</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Lendon</surname><given-names>CL</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Froelich</surname><given-names>S</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Pickering-Brown</surname><given-names>S</given-names></name><name><surname>Chakraverty</surname><given-names>S</given-names></name><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name><name><surname>Hackett</surname><given-names>J</given-names></name><name><surname>Adamson</surname><given-names>J</given-names></name><name><surname>Lincoln</surname><given-names>S</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Stevens</surname><given-names>M</given-names></name><name><surname>de Graaff</surname><given-names>E</given-names></name><name><surname>Wauters</surname><given-names>E</given-names></name><name><surname>van Baren</surname><given-names>J</given-names></name><name><surname>Hillebrand</surname><given-names>M</given-names></name><name><surname>Joosse</surname><given-names>M</given-names></name><name><surname>Kwon</surname><given-names>JM</given-names></name><name><surname>Nowotny</surname><given-names>P</given-names></name><name><surname>Che</surname><given-names>LK</given-names></name><name><surname>Norton</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Reed</surname><given-names>LA</given-names></name><name><surname>Trojanowski</surname><given-names>J</given-names></name><name><surname>Basun</surname><given-names>H</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Neystat</surname><given-names>M</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Dark</surname><given-names>F</given-names></name><name><surname>Tannenberg</surname><given-names>T</given-names></name><name><surname>Dodd</surname><given-names>PR</given-names></name><name><surname>Hayward</surname><given-names>N</given-names></name><name><surname>Kwok</surname><given-names>JB</given-names></name><name><surname>Schofield</surname><given-names>PR</given-names></name><name><surname>Andreadis</surname><given-names>A</given-names></name><name><surname>Snowden</surname><given-names>J</given-names></name><name><surname>Craufurd</surname><given-names>D</given-names></name><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Owen</surname><given-names>F</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>van Swieten</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>T</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name></person-group><article-title>Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>702</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">9641683</pub-id><pub-id pub-id-type="doi">10.1038/31508</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Murrell</surname><given-names>JR</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Klug</surname><given-names>A</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name></person-group><article-title>Mutation in the tau gene in familial multiple system tauopathy with presenile dementia</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>7737</fpage><lpage>7741</lpage><pub-id pub-id-type="pmid">9636220</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.13.7737</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Gijselinck</surname><given-names>I</given-names></name><name><surname>Zee</surname><given-names>J van der</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Wils</surname><given-names>H</given-names></name><name><surname>Pirici</surname><given-names>D</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Vandenberghe</surname><given-names>R</given-names></name><name><surname>Dermaut</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>JJ</given-names></name><name><surname>van Duijn</surname><given-names>C</given-names></name><name><surname>Peeters</surname><given-names>K</given-names></name><name><surname>Sciot</surname><given-names>R</given-names></name><name><surname>Santens</surname><given-names>P</given-names></name><name><surname>De Pooter</surname><given-names>T</given-names></name><name><surname>Mattheijssens</surname><given-names>M</given-names></name><name><surname>Broeck</surname><given-names>M Van den</given-names></name><name><surname>Cuijt</surname><given-names>I</given-names></name><name><surname>Vennekens</surname><given-names>K</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Kumar-Singh</surname><given-names>S</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21</article-title><source>Nature</source><year>2006</year><volume>442</volume><fpage>920</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">16862115</pub-id><pub-id pub-id-type="doi">10.1038/nature05017</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Pickering-Brown</surname><given-names>SM</given-names></name><name><surname>Gass</surname><given-names>J</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Lindholm</surname><given-names>C</given-names></name><name><surname>Snowden</surname><given-names>J</given-names></name><name><surname>Adamson</surname><given-names>J</given-names></name><name><surname>Sadovnick</surname><given-names>AD</given-names></name><name><surname>Rollinson</surname><given-names>S</given-names></name><name><surname>Cannon</surname><given-names>A</given-names></name><name><surname>Dwosh</surname><given-names>E</given-names></name><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Melquist</surname><given-names>S</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Berger</surname><given-names>Z</given-names></name><name><surname>Eriksen</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>T</given-names></name><name><surname>Zehr</surname><given-names>C</given-names></name><name><surname>Dickey</surname><given-names>CA</given-names></name><name><surname>Crook</surname><given-names>R</given-names></name><name><surname>McGowan</surname><given-names>E</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name></person-group><article-title>Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17</article-title><source>Nature</source><year>2006</year><volume>442</volume><fpage>916</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">16862116</pub-id><pub-id pub-id-type="doi">10.1038/nature05016</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skibinski</surname><given-names>G</given-names></name><name><surname>Parkinson</surname><given-names>NJ</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Chakrabarti</surname><given-names>L</given-names></name><name><surname>Lloyd</surname><given-names>SL</given-names></name><name><surname>Hummerich</surname><given-names>H</given-names></name><name><surname>Nielsen</surname><given-names>JE</given-names></name><name><surname>Hodges</surname><given-names>JR</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Thusgaard</surname><given-names>T</given-names></name><name><surname>Brandner</surname><given-names>S</given-names></name><name><surname>Brun</surname><given-names>A</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name><name><surname>Gade</surname><given-names>A</given-names></name><name><surname>Johannsen</surname><given-names>P</given-names></name><name><surname>Sorensen</surname><given-names>SA</given-names></name><name><surname>Gydesen</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>EM</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>806</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">16041373</pub-id><pub-id pub-id-type="doi">10.1038/ng1609</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dumanchin</surname><given-names>C</given-names></name><name><surname>Camuzat</surname><given-names>A</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Verpillat</surname><given-names>P</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Saugier-Veber</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Penet</surname><given-names>C</given-names></name><name><surname>Charbonnier</surname><given-names>F</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group><article-title>Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism</article-title><source>Hum Mol Genet</source><year>1998</year><volume>7</volume><fpage>1825</fpage><lpage>1829</lpage><pub-id pub-id-type="pmid">9736786</pub-id><pub-id pub-id-type="doi">10.1093/hmg/7.11.1825</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Adamson</surname><given-names>J</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name><name><surname>Waring</surname><given-names>S</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>T</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Pickering-Brown</surname><given-names>S</given-names></name><name><surname>Owen</surname><given-names>F</given-names></name><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Craufurd</surname><given-names>D</given-names></name><name><surname>Snowden</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name></person-group><article-title>Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia</article-title><source>Ann Neurol</source><year>1999</year><volume>46</volume><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">10443890</pub-id><pub-id pub-id-type="doi">10.1002/1531-8249(199908)46:2&#x0003c;243::AID-ANA14&#x0003e;3.0.CO;2-L</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>Van Swieten</surname><given-names>JC</given-names></name><name><surname>Joosse</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>M</given-names></name><name><surname>Tibben</surname><given-names>A</given-names></name><name><surname>Niermeijer</surname><given-names>MF</given-names></name><name><surname>Hillebrand</surname><given-names>M</given-names></name><name><surname>Ravid</surname><given-names>R</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name></person-group><article-title>High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands</article-title><source>Am J Hum Genet</source><year>1999</year><volume>64</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">9973279</pub-id><pub-id pub-id-type="doi">10.1086/302256</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>HR</given-names></name><name><surname>Khan</surname><given-names>MN</given-names></name><name><surname>Janssen</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Perez-Tur</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Ozansoy</surname><given-names>M</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Lantos</surname><given-names>P</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name></person-group><article-title>The genetic and pathological classification of familial frontotemporal dementia</article-title><source>Arch Neurol</source><year>2002</year><volume>58</volume><fpage>1813</fpage><lpage>1816</lpage><pub-id pub-id-type="pmid">11708988</pub-id><pub-id pub-id-type="doi">10.1001/archneur.58.11.1813</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binetti</surname><given-names>G</given-names></name><name><surname>Nicosia</surname><given-names>F</given-names></name><name><surname>Benussi</surname><given-names>L</given-names></name><name><surname>Ghidoni</surname><given-names>R</given-names></name><name><surname>Feudatari</surname><given-names>E</given-names></name><name><surname>Barbiero</surname><given-names>L</given-names></name><name><surname>Signorini</surname><given-names>S</given-names></name><name><surname>Villa</surname><given-names>A</given-names></name><name><surname>Mattioli</surname><given-names>F</given-names></name><name><surname>Zanetti</surname><given-names>O</given-names></name><name><surname>Alberici</surname><given-names>A</given-names></name></person-group><article-title>Prevalence of TAU mutations in an Italian clinical series of familial frontotemporal patients</article-title><source>Neurosci Lett</source><year>2003</year><volume>338</volume><fpage>85</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">12565146</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3940(02)01330-7</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>J van der</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Gijselinck</surname><given-names>I</given-names></name><name><surname>Bogaerts</surname><given-names>V</given-names></name><name><surname>Vandenberghe</surname><given-names>R</given-names></name><name><surname>Santens</surname><given-names>P</given-names></name><name><surname>Caekebeke</surname><given-names>J</given-names></name><name><surname>De Pooter</surname><given-names>T</given-names></name><name><surname>Peeters</surname><given-names>K</given-names></name><name><surname>Lubke</surname><given-names>U</given-names></name><name><surname>Broeck</surname><given-names>M Van den</given-names></name><name><surname>Martin</surname><given-names>JJ</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Dermaut</surname><given-names>B</given-names></name></person-group><article-title>A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD</article-title><source>Brain</source><year>2006</year><volume>129</volume><fpage>841</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">16495329</pub-id><pub-id pub-id-type="doi">10.1093/brain/awl029</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fidani</surname><given-names>L</given-names></name><name><surname>Kalinderi</surname><given-names>K</given-names></name><name><surname>Bostantjopoulou</surname><given-names>S</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Goulas</surname><given-names>A</given-names></name><name><surname>Katsarou</surname><given-names>Z</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Kotsis</surname><given-names>A</given-names></name></person-group><article-title>Association of the Tau haplotype with Parkinson's disease in the Greek population</article-title><source>Mov Dis</source><year>2006</year><volume>21</volume><fpage>1036</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1002/mds.20864</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Hutter</surname><given-names>CM</given-names></name><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Nutt</surname><given-names>JG</given-names></name><name><surname>Higgins</surname><given-names>DS</given-names></name><name><surname>Griffith</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>JW</given-names></name><name><surname>Leis</surname><given-names>BC</given-names></name><name><surname>Kay</surname><given-names>DM</given-names></name><name><surname>Yearout</surname><given-names>D</given-names></name><name><surname>Montimurro</surname><given-names>JS</given-names></name><name><surname>Edwards</surname><given-names>KL</given-names></name><name><surname>Samii</surname><given-names>A</given-names></name><name><surname>Payami</surname><given-names>H</given-names></name></person-group><article-title>Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease</article-title><source>Ann Neurol</source><year>2007</year><volume>62</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">17514749</pub-id><pub-id pub-id-type="doi">10.1002/ana.21157</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pittman</surname><given-names>AM</given-names></name><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Abou-Sleiman</surname><given-names>P</given-names></name><name><surname>Fung</surname><given-names>HC</given-names></name><name><surname>Kaleem</surname><given-names>M</given-names></name><name><surname>Marlowe</surname><given-names>L</given-names></name><name><surname>Duckworth</surname><given-names>J</given-names></name><name><surname>Leung</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Kilford</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>CM</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name></person-group><article-title>Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration</article-title><source>J Med Genet</source><year>2005</year><volume>42</volume><fpage>837</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">15792962</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2005.031377</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verpillat</surname><given-names>P</given-names></name><name><surname>Camuzat</surname><given-names>A</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Thomas-Anterion</surname><given-names>C</given-names></name><name><surname>Puel</surname><given-names>M</given-names></name><name><surname>Belliard</surname><given-names>S</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Didic</surname><given-names>M</given-names></name><name><surname>Michel</surname><given-names>BF</given-names></name><name><surname>Lacomblez</surname><given-names>L</given-names></name><name><surname>Moreaud</surname><given-names>O</given-names></name><name><surname>Sellal</surname><given-names>F</given-names></name><name><surname>Golfier</surname><given-names>V</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Clerget-Darpoux</surname><given-names>F</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group><article-title>Association between the extended tau haplotype and frontotemporal dementia</article-title><source>Arch Neurol</source><year>2002</year><volume>59</volume><fpage>935</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">12056929</pub-id><pub-id pub-id-type="doi">10.1001/archneur.59.6.935</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Pickering-Brown</surname><given-names>S</given-names></name></person-group><article-title>Tau haplotype frequency in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Exp Neurol</source><year>2003</year><volume>181</volume><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">12710929</pub-id><pub-id pub-id-type="doi">10.1016/S0014-4886(03)00024-4</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghidoni</surname><given-names>R</given-names></name><name><surname>Signorini</surname><given-names>S</given-names></name><name><surname>Barbiero</surname><given-names>L</given-names></name><name><surname>Sina</surname><given-names>E</given-names></name><name><surname>Cominelli</surname><given-names>P</given-names></name><name><surname>Villa</surname><given-names>A</given-names></name><name><surname>Benussi</surname><given-names>L</given-names></name><name><surname>Binetti</surname><given-names>G</given-names></name></person-group><article-title>The H2 MAPT haplotype is associated with familial frontotemporal dementia</article-title><source>Neurobiol Dis</source><year>2006</year><volume>22</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">16410051</pub-id><pub-id pub-id-type="doi">10.1016/j.nbd.2005.11.013</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neary</surname><given-names>D</given-names></name><name><surname>Snowden</surname><given-names>JS</given-names></name><name><surname>Gustafson</surname><given-names>L</given-names></name><name><surname>Passant</surname><given-names>U</given-names></name><name><surname>Stuss</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Kertesz</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>PH</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Boone</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Benson</surname><given-names>DF</given-names></name></person-group><article-title>Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>1546</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">9855500</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000fc;ger</surname><given-names>J</given-names></name><name><surname>Kaivorinne</surname><given-names>A-L</given-names></name><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Majamaa</surname><given-names>K</given-names></name><name><surname>Remes</surname><given-names>AM</given-names></name></person-group><article-title>Low prevalence of progranulin mutations in Finnish patients with frontotemporal lobar degeneration</article-title><source>Eur J Neurol</source><year>2008</year><volume>16</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19049508</pub-id><pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02272.x</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Adamson</surname><given-names>J</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Perez-Tur</surname><given-names>J</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>T</given-names></name><name><surname>Bigio</surname><given-names>E</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name></person-group><article-title>Association of an extended haplotype in the tau gene with progressive supranuclear palsy</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>711</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">10072441</pub-id><pub-id pub-id-type="doi">10.1093/hmg/8.4.711</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenham</surname><given-names>PR</given-names></name><name><surname>Price</surname><given-names>WH</given-names></name><name><surname>Blandell</surname><given-names>G</given-names></name></person-group><article-title>Apolipoprotein E genotyping by one-stage PCR</article-title><source>Lancet</source><year>1991</year><volume>337</volume><fpage>1158</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">1674030</pub-id><pub-id pub-id-type="doi">10.1016/0140-6736(91)92823-K</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingelson</surname><given-names>M</given-names></name><name><surname>Fabre</surname><given-names>SF</given-names></name><name><surname>Lilius</surname><given-names>L</given-names></name><name><surname>Andersen</surname><given-names>C</given-names></name><name><surname>Viitanen</surname><given-names>M</given-names></name><name><surname>Almkvist</surname><given-names>O</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name></person-group><article-title>Increased risk for frontotemporal dementia through interaction between tau polymorphism and apolipoprotein E epsilon4</article-title><source>Neuroreport</source><year>2001</year><volume>12</volume><fpage>905</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">11303757</pub-id><pub-id pub-id-type="doi">10.1097/00001756-200104170-00008</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zekanowski</surname><given-names>C</given-names></name><name><surname>Pep&#x00142;o&#x00144;ska</surname><given-names>B</given-names></name><name><surname>Styczy&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Gustaw</surname><given-names>K</given-names></name><name><surname>Ku&#x0017a;nicki</surname><given-names>J</given-names></name><name><surname>Barcikowska</surname><given-names>M</given-names></name></person-group><article-title>Mutation screening of the MAPT and STH genes in Polish patients with clinically diagnosed frontotemporal dementia</article-title><source>Dement Geriatr Cogn Disord</source><year>2003</year><volume>16</volume><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">12826737</pub-id><pub-id pub-id-type="doi">10.1159/000070999</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norio</surname><given-names>R</given-names></name></person-group><article-title>Finnish Disease Heritage I: characteristics, causes, background</article-title><source>Hum genet</source><year>2003</year><volume>112</volume><fpage>441</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">12627295</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>W</given-names></name><name><surname>Fung</surname><given-names>HC</given-names></name><name><surname>Steele</surname><given-names>J</given-names></name><name><surname>Eerola</surname><given-names>J</given-names></name><name><surname>Tienari</surname><given-names>P</given-names></name><name><surname>Pittman</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>A</given-names></name><name><surname>Vrieze</surname><given-names>FW</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name></person-group><article-title>The tau H2 haplotype is almost exclusively Caucasian in origin</article-title><source>Neurosci Letters</source><year>2004</year><volume>21</volume><fpage>183</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2004.05.119</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Kaleem</surname><given-names>M</given-names></name><name><surname>Marlowe</surname><given-names>L</given-names></name><name><surname>Pittman</surname><given-names>AM</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Fung</surname><given-names>HC</given-names></name><name><surname>Duckworth</surname><given-names>J</given-names></name><name><surname>Leung</surname><given-names>D</given-names></name><name><surname>Gibson</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>CM</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name></person-group><article-title>The H1c haplotype at the MAPT locus is associated with Alzheimer's disease</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><fpage>2399</fpage><lpage>2404</lpage><pub-id pub-id-type="pmid">16000317</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddi241</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Yancopoulou</surname><given-names>D</given-names></name><name><surname>Tsutsui</surname><given-names>M</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>Sawcer</surname><given-names>SJ</given-names></name><name><surname>Hodges</surname><given-names>JR</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name></person-group><article-title>Association between tau H2 haplotype and age at onset in frontotemporal dementia</article-title><source>Arch Neurol</source><year>2005</year><volume>62</volume><fpage>1419</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">16157749</pub-id><pub-id pub-id-type="doi">10.1001/archneur.62.9.1419</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>SA</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Stajich</surname><given-names>JM</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Hauser</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>BL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name></person-group><article-title>Linkage disequilibrium and haplotype tagging polymorphism in the Tau H1 haplotype</article-title><source>Neurogenetics</source><year>2004</year><volume>5</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">15459824</pub-id><pub-id pub-id-type="doi">10.1007/s10048-004-0180-5</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gustafson</surname><given-names>L</given-names></name><name><surname>Abrahamson</surname><given-names>M</given-names></name><name><surname>Grubb</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>K</given-names></name><name><surname>Fex</surname><given-names>G</given-names></name></person-group><article-title>Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia</article-title><source>Dement Geriatr Cog Disord</source><year>1997</year><volume>8</volume><fpage>240</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1159/000106637</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>SG</given-names></name><name><surname>Watts</surname><given-names>GD</given-names></name><name><surname>Adamson</surname><given-names>JL</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Umberger</surname><given-names>G</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Ramdeen</surname><given-names>S</given-names></name><name><surname>Lovell</surname><given-names>MA</given-names></name><name><surname>Kimonis</surname><given-names>VE</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name></person-group><article-title>APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD)</article-title><source>Genet Med</source><year>2007</year><volume>9</volume><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17224685</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Perani</surname><given-names>D</given-names></name><name><surname>Archetti</surname><given-names>S</given-names></name><name><surname>Agosti</surname><given-names>C</given-names></name><name><surname>Paghera</surname><given-names>B</given-names></name><name><surname>Bellelli</surname><given-names>G</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name></person-group><article-title>Functional correlates of Apolipoprotein E genotype in Frontotemporal Lobar Degeneration</article-title><source>BMC Neurol</source><year>2008</year><volume>6</volume><fpage>31</fpage><pub-id pub-id-type="pmid">16930470</pub-id><pub-id pub-id-type="doi">10.1186/1471-2377-6-31</pub-id></citation></ref></ref-list></back></article> 